Sriparna Roy

1 week ago | marketscreener.com | Sriparna Roy

Published on 05/30/2025 at 06:30, updated on 05/30/2025 at 07:45 (Reuters) -Regeneron shares fell 9% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD).

1 week ago | today.westlaw.com | Shinjini Ganguli |Sriparna Roy

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another.

1 week ago | marketscreener.com | Sriparna Roy

Published on 05/29/2025 at 07:09, updated on 05/29/2025 at 13:06 (Reuters) -Privately held Stealth BioTherapeutics said on Thursday the U.S. Food and Drug Administration had declined to approve its therapy for an ultra-rare condition called Barth Syndrome, prompting it to cut 30% of its workforce. Barth syndrome, which is estimated to affect around 150 people in the United States, has no approved treatments.

1 week ago | today.westlaw.com | Sriparna Roy |Vijay Kishore |Tasim Zahid

(Reuters) -Privately held Stealth BioTherapeutics said on Thursday the U.S. Food and Drug Administration had declined to approve its therapy for an ultra-rare condition called Barth Syndrome, prompting it to cut 30% of its workforce.

1 week ago | jp.reuters.com | Sriparna Roy

米製薬大手イーライリリーは、非上場の同業サイトワン・セラピューティクスを最大１０億ドルで買収する。写真は、イーライリリーグループのリリー・フランス社の壁に掲げられたリリーのロゴ。２０１８年２月、フランスのフェゲルスハイム近郊ストラスブールで撮影（２０２５年 ロイター/Vincent Kessler） [２７日 ロイター] - 米製薬大手イーライリリー(LLY.N), opens new tabは、非上場の同業サイトワン・セラピューティクスを最大１０億ドルで買収する。両社が２７日に発表した。 サイトワンの株主は、前払い金と特定の目標達成に応じたマイルストーン収入合わせて１０億ドルの現金を受け取る可能性がある。 これによりイーライリリーが入手するサイトワンが開発中の非オピオイド鎮痛薬「ＳＴＣ─００４」は、イーライリリーが片頭痛などの慢性痛向けに開発する薬剤製品の拡大に役立つ。...